Laura Indolfi, PhD, is Co-Founder and Chief Executive Officer. Based on foundational technology she invented in the labs at Massachusetts Institute of Technology (MIT) and Harvard Medical School, she has led PanTher’s business and scientific progress to create its proprietary Sagittari™ drug-development platform, a revolutionary technology for the local administration of cancer therapeutics to treat solid tumors. Under her leadership, the company has advanced its lead drug candidate, PTM-101, from preclinical R&D studies to clinical trials for the treatment of pancreatic cancer. Laura has raised equity and grant funding for PanTher since its inception in 2016 and built an experienced leadership team to guide the company’s success.
Laura has been recognized for her entrepreneurial accomplishments by being named a TED Fellow, one of 21 people chosen annually as the most disruptive and transformative change-makers in the world. Prior to founding PanTher Therapeutics, Laura was a postdoctoral associate at the Harvard-MIT Institute for Medical Engineering and Science and served as an entrepreneur-in-residence at the Massachusetts General Hospital Cancer Center.
She holds a PhD in Biomaterials and MS and BS degrees in Materials Science and Engineering from the University of Naples Federico II in Italy.